GENFIT Reveals 2025 Financial Calendar
GENFIT, a dynamic biopharmaceutical company known for its innovative approaches in addressing rare and life-threatening liver diseases, recently disclosed its provisional financial calendar for the year 2025. With its commitment to enhancing patient lives, GENFIT remains focused on advancing its research initiatives and maintaining transparency with its stakeholders.
Key Dates in GENFIT's Financial Calendar
The following important dates outline GENFIT's financial disclosures and shareholder engagements throughout 2025:
February 27, 2025
Publication of revenue and cash position as of December 31, 2024.
April 24, 2025
Release of Full Year financial statements for 2024. This includes the Universal Registration Document and Annual Financial Report, providing comprehensive insights into the company’s financial health.
May 22, 2025
GENFIT will publish its revenue and cash position for the first quarter of 2025, contributing to ongoing financial clarity and direction.
June 17, 2025
The Annual Shareholders Meeting will take place, where stakeholders will have the opportunity to engage with the management team and discuss the company’s strategic outlook.
September 22, 2025
Half-year 2025 financial statements will be published, detailing GENFIT’s performance and progress during the first half of the year.
November 20, 2025
Publication of revenue and cash position at September 30, 2025, rounding out the year with comprehensive financial insights.
This calendar is subject to change, and stakeholders are encouraged to stay informed.
About GENFIT
Headquartered in Lille, France, with offices in Paris, Zurich, and Cambridge, MA, GENFIT has established itself as a pioneer in the realm of liver disease research. Their dedication to addressing rare and life-threatening conditions has resulted in an extensive pipeline of programs in various stages of development. The company primarily focuses on acute-on-chronic liver failure (ACLF) and boasts a diversified R&D portfolio featuring five key assets: VS-01, NTZ, SRT-015, CLM-022, and VS-02-HE.
GENFIT's ambition goes beyond chronic liver diseases, with research extending to cholangiocarcinoma (CCA), urea cycle disorder (UCD), and organic acidemia (OA). The company’s commitment to tackling unmet medical needs was underscored by the accelerated approval of Iqirvo® (elafibranor) by various regulatory bodies for the treatment of primary biliary cholangitis (PBC).
Innovation in Diagnostic Solutions
In addition to developing therapeutic candidates, GENFIT has established a robust diagnostic franchise. This includes NIS2+® which targets metabolic dysfunction-associated steatohepatitis (MASH) and TS-01 focused on blood ammonia levels. Such innovations reflect GENFIT's holistic approach to liver health and disease management.
Company Growth and Developments
With a heritage spanning over two decades, GENFIT has cultivated a rich scientific foundation, propelling its evolution as a leader in liver disease solutions. In 2021, Ipsen emerged as a significant stakeholder, acquiring an 8% equity interest in the company, further solidifying trust and investment in GENFIT's future.
This strategic partnership is expected to foster continued advancements in research and provide additional resources to drive translation from bench to bedside, enhancing the potential for successful outcomes for patients in need.
Frequently Asked Questions
What is GENFIT's main focus?
GENFIT concentrates on developing innovative treatments for rare liver diseases, particularly acute-on-chronic liver failure.
What is included in the financial calendar?
The financial calendar outlines key dates for the release of financial metrics, shareholder meetings, and annual reports for 2025.
What assets are under development by GENFIT?
GENFIT is developing five key assets: VS-01, NTZ, SRT-015, CLM-022, and VS-02-HE, targeting various liver diseases and conditions.
Where is GENFIT headquartered?
GENFIT is headquartered in Lille, France, with additional offices in Paris, Zurich, and Cambridge, MA.
Is GENFIT listed on stock exchanges?
Yes, GENFIT is listed on the Nasdaq Global Select Market and the Euronext regulated market in Paris under the ticker GNFT.
